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Edited by Laszlo NagyAbstract Abnormally elevated expression of cyclooxygenase-2
(COX-2) has been frequently observed in transformed or malig-
nant cells, and certain non-steroidal anti-inﬂammatory drugs with
COX-2 inhibitory activity exert anti-neoplastic or chemopreven-
tive eﬀects. Contrary to this notion, we have found that a novel
alkylphospholipid type antitumor agent ET-18-O-CH3 (1-O-
octadecyl-2-O-methyl-glycero-3-phosphocholine) induces COX-
2 expression in H-ras transformed human breast epithelial cells
(MCF10A-ras) while it causes apoptosis at the same concentra-
tion range. The addition of a selective COX-2 inhibitor SC-
58635 and COX-2 gene knock down with the siRNA blocked
ET-18-O-CH3-induced apoptosis, suggesting that COX-2 induc-
tion by this drug is causally linked to its apoptosis inducing activ-
ity. ET-18-O-CH3 enhanced the transcriptional activities of cyclic
AMP response element which is a key regulator of COX-2 expres-
sion. 15-Deoxy-D12,14 prostaglandin J2 is, an endogenous ligand
for peroxisome proliferator-activated receptor c (PPARc), has
been known to possess proapoptotic potential in diverse cell types.
ET-18-O-CH3 treatment resulted in elevated release of 15d-PGJ2
and DNA binding and transcriptional activity of PPARc. Based
on these ﬁndings, it is likely that ET-18-O-CH3 induces COX-2
expression and production of 15d-PGJ2 which may mediate the
ET-18-O-CH3-induced apoptosis in MCF10A-ras cells.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Cyclooxygenase (COX) initiates the conversion of arachido-
nate to a series of prostaglandins (PGs) and thromboxanes.
Two isoforms of COX, i.e., COX-1 and COX-2, have been
identiﬁed. COX-1, which is constitutively expressed in almost
all tissues, is important for the maintenance of homeostatic
functions, whereas COX-2, as an inducible isozyme, is tran-
siently upregulated by pro-inﬂammatory cytokines, growth
factors, tumor promoters, etc. [1]. Abnormal upregulation of
COX-2 has been implicated in the pathogenesis of various hu-
man malignancies. There has been substantial body of data
suggesting that COX-2 overexpression provides tumor cells
with survival advantage leading to resistance to apoptosis
and increased invasiveness or angiogenesis [2–4]. Conversely,*Corresponding author. Fax: +82 2 874 9775.
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doi:10.1016/j.febslet.2005.09.094selective COX-2 inhibitors have been shown to exert anti-car-
cinogenic activity [5,6]. Therefore, inhibition of COX-2 has
been recognized as one of the most promising strategies for
cancer prevention or treatment.
However, induction of COX-2 does not necessarily contrib-
ute to the cell survival or tolerance to proapoptotic insult.
Thus, certain anticancer agents with pro-apoptotic activity
were found to upregulate COX-2 expression in human hepatic
myoﬁbroblasts cells [7] and neuroglioma cells [8]. According to
these studies, COX-2 inhibition by non-steroidal anti-inﬂam-
matory drugs (NSAID) blunted the anti-proliferative eﬀect
of these compound, suggesting that COX-2-derived PGs may
be implicated in sensitizing these cells to apoptotic death.
Moreover, in line with a possible proapoptotic function of
COX-2, a major COX-2 product prostaglandin E2 (PGE2) [8]
as well as 15-deoxy-D12,14-PGJ2 (15d-PGJ2) [9–11], a ligand
of peroxisome proliferator-activated receptor c (PPARc), in-
duced apoptosis in several types of cancer cells. Nonetheless,
the molecular mechanism linking upregulation of COX-2 to
induction of apoptosis has not been resolved yet.
ET-18-O-CH3 (edelfosine; 1-O-octadecyl-2-O-methyl-rac-
glycero-3-phosphocholine) is a synthetic analogue of 2-lyso-
phosphatidylcholine that has been found to target cellular
membranes and to exert potent anti-neoplastic eﬀects [12,13].
ET-18-O-CH3 has a broad spectrum of anti-tumorigenic eﬀects
[14–17]. The compound has been known to be a potent inducer
of apoptosis in tumor cells, especially in leukemic cells, while
sparing normal cells [18–20]. Inhibition of protein kinase C,
phospholipase C, phosphatidylinositol 3-kinase, CTP: phospho-
choline cytidylyltransferase, and coenzyme A-independent
transacylase as well as blocking of arachidonate-phospholipid
remodeling contributes to ET-18-O-CH3-induced apoptosis
[20–27]. ET-18-O-CH3-induced apoptosis was accompanied by
disruption of the mitochondrial transmembrane potential and
activation of caspase-3 [15,28]. It also induces cell death by intra-
cellular activation of the death receptor Fas/CD95 [18,29,30].
Here, we report that upregulation of COX-2 contributes to
apoptotic death of the ras-transformed human mammary epi-
thelial cells treated with the anti-cancer drug ET-18-O-CH3.2. Materials and methods
2.1. Materials
ET-18-O-CH3 was purchased from BIOMOL Research Laborato-
ries, Inc. (Plymouth Meeting, PA, USA). SC58635, a speciﬁc COX-
2 inhibitor, was kindly provided by Pharmacia Korea. PGE2 andblished by Elsevier B.V. All rights reserved.
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USA). Dulbeccos modiﬁed Eagles medium (DMEM)/F-12, heat-inac-
tivated horse serum, L-glutamine, and penicillin/streptomycin/fungi-
zone mixture were products of Gibco-BRL (Grand Island, NY,
USA). Insulin, cholera toxin, hydrocortisone, recombinant epidermal
growth factor, and actin antibody were purchased from the Sigma
Chemical Co. (St. Louis, MO, USA). Antibodies against poly(ADP-
ribose)polymerase (PARP) and COX-2 were from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). Cleaved PARP antibody was
purchased from Cell Signaling Technology (Beverly, MA, USA). Sec-
ondary antibodies were obtained from Zymed Laboratories Inc. (San
Francisco, CA, USA). The ECL chemiluminescent detection reagent
was purchased from Amersham Co. (Arlington Heights, IL, USA).
A series of human COX-2 promoter deletion constructs ligated to
luciferase gene were described previously [31]. The putative peroxi-
some-proliferator reactive element (PPRE) ﬁreﬂy luciferase reporter
construct (pPPRE-Luc) was kindly provided by Dr. Kang-Yell Choi
(Yonsei University, Seoul, Korea). [c-32P]ATP was the product of
NEN Life Science (Boston, MA, USA). ET-18-O-CH3 was dissolved
in 50% ethanol. Other substances were dissolved in DMSO and was
further diluted with culture medium.2.2. Cell culture
The MCF10A cell line transfected with a virus carrying the H-ras
oncogene (MCF10A-ras) was cultured as described previously [32].
The cells were cultured in DMEM/F-12 medium supplemented with
5% heat-inactivated horse serum, 10 lg/ml insulin, 100 ng/ml cholera
toxin, 0.5 lg/ml hydrocortisone, 20 ng/ml recombinant EGF, 2 mM
L-glutamine, and 100 lg/ml penicillin/streptomycin/fungi zone mixture
at 37 C in a 5% CO2 atmosphere.2.3. Cell growth assay
MCF10A-ras cells at 50–60% conﬂuence were inoculated into the
plate and exposed to the medium containing chemicals. The cell viabil-
ity was determined by the trypan blue exclusion method or the conven-
tional MTT reduction assay as described previously [16,33]. All
samples were prepared in triplicates.2.4. Measurement of PGs
MCF10A-ras cells cultured in 6-well plates were treated with ET-18-
O-CH3 with or without SC58635 for 3 days. The amounts of PGE2
released into media were measured using the enzyme-immunoassay
kit (Amersham Biosciences Corp., NJ, USA) according to the manu-
facturers instructions. Brieﬂy, 50 ll of culture medium previously cen-
trifuged at 200 · g for 10 min was mixed with 50 ll PGE2 antibody
solution in the plate coated with goat anti-mouse IgG followed by
incubation on ice for 3 h. After 50 ll horseradish peroxidase conjugate
PGE2 was added to the reaction mixture, the plate was kept on ice for
additional 1 h. After aspiration and rinse four times with washing buf-
fer, 150 ll of 3,3 0,5,5 0-tetramethylbenzidine substrate solution was
added and incubation was continued for 30 min at room temperature
in a dark place. The reaction was terminated by addition of 100 ll
of 1 M sulfuric acid, and the absorbance at 450 nm was read by the
ELISA reader. PGE2 was quantitated using a standard curve con-
structed with known concentrations of PGE2. Likewise, 15d-PGJ2
was assayed using an enzyme immunoassay kit (Assay Designs Inc.,
Ann Arbor, MI, USA).2.5. In situ nick end-labeling (TUNEL)
To detect apoptosis at a single cell level, enzymatic in situ nick end-
labeling (TUNEL) was carried out with an in situ death detection kit
(Boehringer Mannheim, Mannheim, Germany), according to a manu-
factures protocol. Brieﬂy, MCF10A-ras cells were cultured in a cham-
ber slide in the absence or presence of ET-18-O-CH3 for 3 days. The
cells were ﬁxed for 30 min in 10% neutral-buﬀered formalin solution at
room temperature. Endogenous peroxidase was inactivated by incuba-
tion with 0.3% (v/v) hydrogen peroxide in methanol for 1 h at room
temperature and further incubated in a permeabilizing solution
(0.1% sodium citrate and 0.1% Triton X-100) for 2 min at 4 C. The
cells were labeled by incubation with the TUNEL reaction mixture
for 60 min at 37 C followed by labeling with peroxidase-conjugated
anti-ﬂuorescein anti-goat antibody (Fab fragment) for additional30 min. After being stained with diaminobenzidine for 10 min, cells
were rinsed with phosphate-buﬀered saline (PBS) and mounted with
50% glycerol.
2.6. Measurement of sub-diploid DNA
MCF10A-ras cells plated at a density of 2 · 105 cells in 6-well plates
were treated with ET-18-O-CH3 in the presence or absence of SC58635
for 24 h. The cells were washed, trypsinized, collected by centrifuged at
200 · g for 5 min, ﬁxed with 1 ml of 70% cold ethanol and stored at
20 Cuntil use.After centrifugationat 1300·g for10 min, theﬁxed cells
were stained with PBS containing 0.1% Triton X-100, 0.1 mM EDTA
(pH7.4), 10 lg/mlRNaseA, and 50 lg/mlPI, and 10000 cells per sample
were analyzed by a FACScalibur instrument (Backton–Dicknson,
USA). The DNA histograms were further analyzed by CellQuest Pro
software to calculate the proportion of sub-diploid cell population.
2.7. Measurement of mitochondrial transmembrane potential
To measure the mitochondrial transmembrane potential (Dwm), the
lipophilic cationic probe TMRE was used. MCF10A-ras cells were cul-
tured in 4 chamber slide glasses (Nunc, IL, USA). After treatment, the
cells were rinsed with PBS and incubated with TMRE (150 nM) in the
fresh media for 30 min at 37 C. The cells were examined under a con-
focal microscope (Leica Microsystems Heidelberg GmbH, Heidelberg,
Germany) with the ﬂuorescence excitation at 488 nm and emission at
590 nm.
2.8. Western blot analysis
Treated MCF10A-ras cells were washed with PBS and harvested
after digestion with lysis buﬀer (150 mM NaCl, 0.5% Triton X-100,
50 mM Tris–HCl, pH 7.4, 25 mM NaF, 20 mM EGTA, 1 mM DTT,
1 mM Na3VO4, protease inhibitor cocktail tablet). Cellular debris
was removed by centrifugation at 23000 · g for 15 min at 4 C. The
protein concentration was determined by using the BCA protein assay
kit (Pierce Biotechnology, Inc., Rockford, IL). After addition of sam-
ple loading buﬀer, proteins were electrophoresed on a 12.5% SDS–
polyacrylamide gel. The proteins were transferred to polyvinylidene
diﬂuoride membranes at 300 mA for 3 h. The membranes were blocked
in 5% dried milk reconstituted in 0.1% Tween 20 in PBS (PBST). The
blots were then incubated with primary antibodies (COX-2, PPARc,
caspase-3) in 3% dried milk/PBST. The blots were washed three times
with PBST, and incubated with horseradish peroxidase-conjugated sec-
ondary antibodies in 3% dried milk/PBST for 1 h. The blots were
washed again three times with PBST, and immunoreactive protein
complexes were detected by the ECL detection reagent according to
the manufacturers instructions and visualized with X-ray ﬁlm.
2.9. Reverse-transcriptase polymerase chain reaction (RT-PCR)
Total RNA was isolated from MCF10A-ras cells using TRIzol
(Invitrogen, Carlsbad, CA, USA). One lg of total RNA was reverse-
transcribed with murine leukemia virus reverse transcriptase (Promega,
Madison, WI, USA) at 42 C for 50 min and 72 C for 15 min. The cy-
cling conditions were as follows: 3 min at 95 C followed by 35 cycles of
95 C, 30 s; 63 C, 1 min; 72 C, 1 min of COX-2; 26 cycles of 94 C,
1 min; 63 C, 2 min; 72 C, 2 min of the house keeping gene, glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) followed by a ﬁnal exten-
sion at 72 C for 10 min. The primer pairs (forward and reverse,
respectively) and the size of the expected products were as follows:
COX-2, 5 0-CGGGATCCATGCTCGCCCGCGCCCTGCTGC-30 and
5 0-GCTCTAGAGCCTACAGTTCAGTCGAACGTTC-3 0, 1800 base
pair; GAPDH, 5 0-TGAAGGTCGGTGTCAACGGATTTGGC-3 0
and 5 0-CATGTAGGCCATGAGGTCCACCAC-3 0, 983 base pair.
Ampliﬁcation products were analyzed on 1.2% agarose gel electro-
phoresis, stained with ethidium bromide, and photographed under
ultraviolet light.
2.10. Transient transfection and the luciferase assay
MCF10A-ras cells seeded at a density of 2 · 105/well in a 6-well dish
were grown to 60–70% conﬂuence in complete growth media. The cells
were co-transfected with 2 lg of plasmid DNA constructs and 0.5 lg of
pCMV-b galactosidase control vector with DOTAP liposomal trans-
fection reagent (Roche Applied Science, Mannheim, Germany) accord-
ing to the manufacturers instructions. After 12-h transfection, the cells
were treated with ET-18-O-CH3 for additional 6 h and then washed
Fig. 1. Eﬀects of ET-18-O-CH3 on growth of MCF10A-ras cells. (A)
The trypan blue dye exclusion method. Ten thousands of MCF10A-ras
cells were inoculated into 35-mm dishes and exposed to the medium for
3 days with various concentrations (0, 1, 2.5, 5 lg/ml) of ET-18-O-
CH3. Treated cells were trypsinized followed by staining with trypan
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WI). The activities of ﬁreﬂy luciferase in the cell lysates were measured
using the luciferase reporter assay system according to the manufac-
turers instructions (Promega, Madison, WI) by Luminoskan lumino-
meter (Thermo Labsystems, Helsinki, Finland). b-Galactosidase
activity was measured by using the commercially available assay kit
(Promega, Madison, WI). The relative luciferase activity was obtained
by normalizing the ﬁreﬂy luciferase activity against the b-galactosidase
activity.
2.11. COX-2 siRNA transfection
An oligonucleotide sequence for COX-2 siRNA was selected to
knock down COX-2 expression by utilizing the siRNA Target Finder
software at www.invitrogen.com. The human COX-2 speciﬁc siRNA
(5 0-AAG GGC UCU AGU AUA AUA GGA GAG G-30) and the
non-speciﬁc siRNA (5 0-AAG AGG GCU CGA UUA UUA AGG
AGG G-3 0) were provided by Invitrogen (Carlsbad, CA, USA).
MCF10A-ras cells were transfected with an oligonucleotide sequence
for COX-2 siRNA or non-speciﬁc siRNA for 24 h with DOTAP lipo-
somal transfection reagent (Roche Applied Science, Mannheim, Ger-
many) according to the manufacturers instructions. After 24 h
transfection, the cells were treated with ET-18-O-CH3 or vehicle alone
for 6 h.
2.12. Preparation of nuclear extracts
MCF10A-ras cells were cultured in 100-mm dishes in the absence or
presence of ET-18-O-CH3. Cells were gently washed with cold PBS,
scraped, and centrifuged at 1300 · g for 5 min. Pellets were suspended
in cold hypotonic buﬀer [10 mM HEPES, pH 7.9, 1.5 mM MgCl2,
0.3 mM EDTA, 0.1 mM phenylmethylsulfonylﬂuoride (PMSF)]. The
lysates were incubated for 10 min on ice and then centrifuged at
20200 · g for 15 min at 4 C. The pellets were washed with hypotonic
buﬀer and resuspended in hypertonic buﬀer (30 mM HEPES, 1.5 mM
MgCl2, 0.3 mM EDTA, 10% glycerol, 450 mM NaCl, 0.1 mM PMSF)
in ice for 30 min during rocking followed by centrifugation at
20200 · g for 15 min. After determination of the protein concentra-
tion, the supernatant was stored at 80 C before use.
2.13. Electrophoretic mobility shifty assay
The oligonucleotides harboring the PPRE consensus sequence (5 0-
CCAAGGTCAAAGGT-3 0) were end-labeled with [c-32P] ATP using
T4 polynucleotide kinase (Takara, Japan). The nuclear protein (7–
10 lg) was incubated with 8.5 ll of incubation buﬀer (30 mM
HEPES, pH 7.9, 1.5 mM MgCl2, 0.3 mM EDTA, pH 8.0, 10% glyc-
erol), 2.5 ll polydI-dC (0.5 lg/ll), and the hypertonic buﬀer was
added up to 20 ll of total volume. The reaction mixture was pre-
incubated at room temperature for 15 min. The labeled oligonucleo-
tide (50000–100000 cpm) was added and incubated for 30 min at
room temperature for DNA-binding reactions. To ensure the speciﬁc-
ity of the binding, a competition experiment was carried out by
adding the excess unlabeled oligonucleotide to the reaction mixture
before addition of the labeled oligonucleotide. Samples were sepa-
rated on the 6% acrylamide gels at 150 mA in 0.25· tris–borate–
EDTA buﬀer. After vacuum-dried, the gel was exposed to X-ray ﬁlm
for autoradiography at 70 C.blue, and viable cells were counted by a hematocytometer. Bars
represent means ± S.E.M. of triplicate experiments. A signiﬁcant
diﬀerence in the relative viability between treated cells and solvent
controls is indicated with an asterisk. (B) Morphological changes in the
MCF10A-ras cells treated with ET-18-O-CH3 (2.5 lg/ml) for 1 day.
Visualized by phase-contrast microscopy. (C) ET-18-O-CH3-induced
proteolytic cleavage of caspase-3 and PARP. MCF10A-ras cells were
exposed to indicated concentrations of ET-18-O-CH3 for 3 days.
Protein from cell lysates was resolved by SDS–PAGE by Western blot
using antibodies against caspase-3, PARP, and cleaved-PARP.3. Results
3.1. ET-18-O-CH3-induced apoptosis in MCF10A-ras cells
Treatment of MCF10A-ras cells with ET-18-O-CH3 inhib-
ited the cell growth in a concentration dependent manner
(Fig. 1A). ET-18-O-CH3 treatment resulted in distinct mor-
phological changes including rapid blebbing of plasma mem-
brane and nuclear disintegration that are characteristic of
apoptotic cell death (Fig. 1B). Moreover, MCF10A-ras cells
treated with ET-18-O-CH3 exhibited proteolytic cleavage of
caspase-3 and the DNA repair enzyme PARP that are typical
biochemical changes frequently observed in cells undergoing
apoptotic death (Fig. 1C).3.2. ET-18-O-CH3 upregulated COX-2 expression while
inducing apoptosis
Activated ras oncogene has been associated with upregula-
tion of COX-2 in breast cancer cells [34], colorectal adenomas
[35,36] and non-small cell lung cancer [37]. In recognition of
this notion, we attempted to determine whether ET-18-O-
CH3 could induce apoptosis through downregulation of
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CH3-induced COX-2 expression at both protein and mRNA
levels in a concentration dependent manner, whereas basal
COX-2 expression in MCF10A-ras cells remained relatively
low (Fig. 2A and B). Unlike COX-2, the expression of COX-
1 was not aﬀected by ET-18-O-CH3 treatment in MCF10A-
ras cells (data not shown). In parallel with elevated COX-2
expression, PGE2 production was also signiﬁcantly increased
upon ET-18-O-CH3 treatment (Fig. 2C).
3.3. Upregulation of COX-2 was causally linked to ET-18-O-
CH3-induced apoptosis in MCF10A-ras cells
Although upregulation of COX-2 expression has been
frequently associated with resistance to apoptosis, ET-18-O-
CH3-induced apoptosis and COX-2 expression in MCF10A-
ras cells under the same experiment conditions. To examine
whether ET-18-O-CH3-induced COX-2 expression contributes
to induction of apoptosis, a selective COX-2 inhibitor
SC58635 was utilized. SC58635 inhibited ET-18-O-CH3-in-Fig. 2. Eﬀects of ET-18-O-CH3 on expression of COX-2 and PGE2
production in MCF10A-ras cells. (A) Western blot analysis of COX-2
protein expression. MCF10A-ras cells were treated with various
concentrations of ET-18-O-CH3 for 3 days. Protein extracts from the
cells were immunoblotted with anti-COX-2 antibody. (B) Determina-
tion of the relative amount of COX-2 mRNA. Total RNA was
extracted with TRIzol, and RT-PCR for COX-2 mRNA transcripts
was carried out as described under Section 2.9. GAPDH was used as
an equal loading control. (C) ET-18-O-CH3-induced PGE2 production
in MCF10A-ras cells. PGE2 production was measured 3 days later by
using the PGE2 enzyme immunoassay kit following the manufacturers
protocol. A signiﬁcant diﬀerence between treated cells and solvent
controls is indicated with an asterisk (P < 0.01).duced production of PGE2 in MCF10A-ras cells (Fig. 3A).
We observed that SC58635, at a concentration that blocks
COX-2, protected MCF10A-ras from ET-18-O-CH3-induced
proteolytic cleavage of caspase-3 (Fig. 3B). The same concen-
tration of SC58635 inhibited the ET-18-O-CH3-induced DNA
fragmentation and lowered the sub G0/G1 proportion as mea-
sured by TUNEL staining and ﬂow cytometry, respectively
(Fig. 3C). The pharmacologic inhibition of COX-2 also re-
stored the mitochondrial transmembrane potential (Dwm)
which was perturbed in ET-18-O-CH3 treated cells (Fig. 3C).
Likewise, the ET-18-O-CH3-induced PARP cleavage was abol-
ished upon direct COX-2 gene knock down by employing the
COX-2 siRNA (Fig. 3D), lending further support to the notion
that upregulation of COX-2 expression is causally linked to
induction of apoptosis in MCF10A-ras cells.
3.4. ET-18-O-CH3 enhanced the COX-2 promoter activity
The regulation of COX-2 synthesis occurs mainly at the tran-
scriptional level, although mRNA stabilization is also involved
in response to speciﬁc signals. The types and nature of stimuli,
signal transduction pathways, and transcription factors in-
volved in the induction ofCOX-2 gene expression are extremely
diversiﬁed and cell speciﬁc. Several cis-acting elements are
found in the COX-2 promoter, such as nuclear factor-jB
(NF-jB), nuclear factor-interleukin-6 (NF-IL6), cyclic AMP
response element (CRE), and E-box [38,39]. In order to deter-
mine which transcription factors are involved in ET-18-O-CH3-
induced COX-2 expression, MCF10A-ras cells were transiently
transfected with human COX-2 promoter luciferase constructs
(1432/+59) (Fig. 4A) and challenged with ET-18-O-CH3 for
6 h. Treatment with ET-18-O-CH3 resulted in about a 6-fold in-
crease in the COX-2 promoter (1432/+59) activity. To eluci-
date the critical region of the COX-2 promoter responsible
for COX-2 expression by ET-18-O-CH3, we utilized a series
of COX-2 deletion constructs (1432/+59, 327/+59, 220/
+59, 124/+59, and 52/+59). The COX-2 promoter activity
was most prominent when the 327/+59 promoter construct
was used (Fig. 4B). As the promoter length was shortened,
COX-2 activities were diminished gradually. It is noticeable
that the 52/+59 construct exhibited an approximately 97%
loss of the COX-2 promoter activity compared with the
327/+59 construct. A CRE is present between nucleotides
59 and 53, suggesting that this element might responsible
for mediating the COX-2 inducing eﬀects of ET-18-O-CH3.
To precisely deﬁne which of these cis-acting elements are in-
volved in ET-18-O-CH3-induced COX-2 promoter activity,
MCF10A-ras cells were transiently transfected with site-speciﬁc
mutant COX-2 promoter constructs. As shown in Fig. 4C,
CRM (327/+59 construct in which mutated at the CRE site)
signiﬁcantly decreased the COX-2 promoter activity in ET-
18-O-CH3-treated cells. The introduction of ILM (mutated at
the NF-IL6 site) resulted in approximately 2-fold reduction,
compared with the wild type 327/+59 construct while little ef-
fect on COX-2 promoter activity was achieved with KBM (mu-
tated at the NF-jB site) (Fig. 4C). These results suggest that
CRE and possibly NF-IL6 play important role in mediating
the induction of COX-2 gene expression.
3.5. ET-18-O-CH3 induced production of 15d-PGJ2 and
expression as well as activation of PPARc
To clarify how COX-2 upregulation by ET-18-O-CH3 leads
to induction of apoptosis in MCF10A-ras cells, we attempted
Fig. 3. Eﬀects of the speciﬁc COX-2 inhibitor SC58635 on the ET-18-O-CH3-induced apoptosis in MCF10A-ras cells. (A) Relative amount of PGE2
released in the media following co-treatment of ET-18-O-CH3 (2.5 lg/ml) for 3 days with SC58635 in the MCF10A-ras cells. (B) Eﬀects of SC58635
on ET-18-O-CH3-induced COX-2 expression as well as caspase-3 activation measured by Western blot analysis. MCF10A-ras cells were co-treated
with ET-18-O-CH3 (2.5 lg/ml) and 10, 25, 50 lM of SC58635 for 3 days. Protein extracts from the cells were immunoblotted with anti-COX-2, anti-
caspase-3, and anti-actin antibodies. (C) SC58635 attenuation of ET-18-O-CH3-induced apoptosis as determined by TUNEL, ﬂow cytometry, and
mitochondrial transmembrane permeability (Dwm) changes. Cells were treated with ET-18-O-CH3 (2.5 lg/ml) in the absence or presence of SC58635
(50 lM) for 1 day. (D) Eﬀects of COX-2 siRNA on the ET-18-O-CH3-induced COX-2 expression and cleaved PARP measured by Western blot
analysis. MCF10A-ras cells were transfected with 20 nM non-speciﬁc and COX-2 speciﬁc siRNA before ET-18-O-CH3 treatment.
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ucts, 15d-PGJ2, an endogenous PPARc ligand, has been
known to possess pro-apoptotic potential in diverse cancer
cells [40]. To examine whether 15d-PGJ2 can mediate ET-18-
O-CH3-induced apoptosis, we measured the production of this
cyclopentenone PG in the MCF10A-ras cells treated with ET-
18-O-CH3. 15d-PGJ2 production was signiﬁcantly elevated
after treatment of ET-18-O-CH3 (Fig. 5A). Again, SC58635
suppressed the production of 15d-PGJ2 induced by ET-18-O-CH3 (Fig. 5A). We also observed that exogenously added
15d-PGJ2 inhibited the growth of MCF10A-ras cells
(Fig. 5B) and induced apoptosis in MCF10A-ras cells as re-
vealed by proteolytic cleavage of caspase-3 (Fig. 5C). As an
endogenous ligand of PPARc, 15d-PGJ2 is likely to exert its
biologic eﬀects in part via PPARc. Moreover, ET-18-O-CH3
activated expression of PPARc as well as COX-2 which pre-
ceded the activation of caspase-3 through proteolytic cleavage
(Fig. 5D). We also observed that ET-18-O-CH3 induced the
Fig. 4. ET-18-O-CH3-induced activation of the COX-2 promoter. (A) A schematic representation of the human COX-2 promoter. (B)
Determination of cis-acting elements of COX-2 promoter. MCF10A-ras cells were transfected with the 2.5 lg of a series of human COX-2 promoter
deletion constructs (1432/+59, 327/+59, 220/+59, 124/+59, 52/+59) ligated to luciferase. (C) Identiﬁcation of the regions responsible for ET-
18-O-CH3-induced promoter activity of the human COX-2 gene. MCF10A-ras cells were transfected with 2.5 lg of a series of human COX-2
pormoter-luciferase constructs (327/+59, KBM; ILM; CRM). KBM represents the 327/+59 COX-2 promoter construct in which the NF-jB site
was mutated. ILM represents the 327/+59 COX-2 promoter construct in which the NF-IL6 site was mutated. CRM refers to the 327/+59 COX-2
promoter construct in which the CRE site was mutated. For the experiments related to B and C, MCF10A-ras cells were transiently co-transfected
with pCOX-2 promoter and pCMV-b galactosidase (0.5 lg) for 24 h by using DOTAP Liposomal Transfection Reagent according to the
manufacturers instructions. Transfectant cells were treated with ET-18-O-CH3 (2.5 lg/ml) for 4 h and the cells were lysed with reporter lysis buﬀer
for measurement of luciferase activity. Luciferase activity represents data that have been normalized to b-galactosidase activity.
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(Fig. 5F) of PPARc in MCF10A-ras cells. Therefore, ET-18-
O-CH3-induced COX-2 expression and subsequent production
of 15d-PGJ2 are likely to contribute to induction of apoptosis
in MCF10A-ras cells.4. Discussion
Multiple lines of evidence indicate that aberrant overexpres-
sion of COX-2 is implicated in inhibition of apoptosis and in-
duced proliferation [2]. Tumor formation and growth are
reduced in animals that are either genetically engineered to
be COX-2 deﬁcient or treated with a pharmacologic inhibitor
of COX-2 [41–43]. The use of NSAIDs has been associated
with a reduced risk of several malignancies through inhibition
of COX-2 activity [44,45]. Moreover intake of the selective
COX-2 inhibitor celecoxib reduced the burden of colorectalpolyps in patients with familial adenomatous polyposis and
has been shown to inhibit experimentally induced carcinogen-
esis [6,46,47]. Inhibition of COX-2 is hence recognized as one
of the most feasible strategies for cancer chemoprevention
and treatment.
Contrary to these ﬁndings, our present study clearly demon-
strates that upregulation of COX-2 is causally linked to ET-18-
O-CH3-induced apoptosis in MCF10A-ras cells as a selective
COX-2 inhibitor blocked the ET-18-O-CH3-induced cell
death. In this study, we found that mutation of the CRE bind-
ing site completely abolished the COX-2 promoter activity,
suggesting that this site located in the COX-2 promoter plays
a crucial role in regulating COX-2 transcription. Knock-down
of COX-2 expression by siRNA also attenuated apoptosis in-
duced by ET-18-O-CH3. Other investigators have also re-
ported that some of agents upregulate COX-2 expression
while inducing apoptosis [7,48]. Thus, sphingosin 1-phosphate,
a bioactive sphingolipid with growth-regulating properties,
Fig. 5. Possible involvement of 15-PGJ2 production in ET-18-O-CH3-induced apoptosis. (A) Production of 15d-PGJ2 in ET-18-O-CH3 treated
MCF10A-ras cells. The amounts of 15d-PGJ2 released into media were measured after treatment of the cells with 2.5 lg/ml of ET-18-O-CH3 for 1
days. (B) 15d-PGJ2 induced anti-proliferative eﬀect in MCF10A-ras cells. Cell viability was measured by the conventional MTT reduction assay after
treatment with 15d-PGJ2 (10 lM) for 1 day. Bars represent means ± S.E.M. of triplicate experiments. (C) 15d-PGJ2 induced apoptosis in MCF10A-
ras cells as evidenced by caspase-3 cleavage. (D) ET-18-O-CH3 induced expression of PPARc, COX-2, and caspase-3 cleavage as determined by
immunoblot analysis. The concentration of ET-18-O-CH3 was 2.5 lg/ml. (E) DNA-binding activity of PPARc in ET-18-O-CH3 treatment MCF10A-
ras cells. Nuclear extracts were prepared from MCF10A-ras cells treated with ET-18-O-CH3 for 30 min and incubated with the [c-P
32] labeled
oligonucleotide harboring PPRE, followed by electrophoretic mobility shifty assay. (F) Relative luciferase activity representing the transcriptional
activity of PPARc. MCF10A-ras cells were transiently co-transfected with pPPRE-Luc and pCMV-b galactosidase for 24 h using DOTAP
Liposomal Transfection Reagent according to the manufacturers instructions. Transfectant cells were treated with ET-18-O-CH3 (2.5 lg/ml) for 6 h
and the cells were lysed with reporter lysis buﬀer for the measurement of luciferase activity.
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2 by NS-398 blunted the anti-proliferative eﬀect of sphingosin
1-phosphate in human hepatic myoﬁbroblasts cells [7]. More
recently, R(+)-methanandamide-induced cell death has been
found to be associated with COX-2 upregulation in human
neuroglioma cells [8]. Some of PGs are known to have proa-
poptotic activity. For instance, 15d-PGJ2, a potent natural li-
gand for PPARc, induces apoptosis in several types ofcancer cells [49,50]. When MCF10A-ras cells were treated with
exogenously added 15d-PGJ2, this cyclopentenone PG induced
apoptosis in MCF10A-ras cells. Moreover, ET-18-O-CH3
treatment augmented production of 15d-PGJ2. Biological
eﬀects of 15d-PGJ2 could be elicited via several distinct mech-
anisms, either PPARc-dependent or -independent. We found
that ET-18-O-CH3 induced expression of PPARc and its sub-
sequent binding to PPRE and transcriptional activity. It has
6286 H.-K. Na et al. / FEBS Letters 579 (2005) 6279–6287been reported that PPRE is located in the 5 0 ﬂanking region of
the COX-2 promoter, and that induction of COX-2 expression
by NSAIDs and PPARc ligands is mediated via this element
[51].
Besides COX-2-dependent induction of apoptosis we
demonstrated in the present work, there might be other mech-
anisms which can also be attributable to ET-18-O-CH3-
induced apoptosis in MCF10A-ras cells. In this context, it is
interesting to note that ET-18-O-CH3-induced apoptosis is
associated with production of reactive oxygen species in p53-
defective hepatocytes [15] and HL-60 cells [28].
Blockade of ET-18-O-CH3-induced apoptosis by SC58635
may have clinical implications. Recently, the chemotherapeutic
agent paclitaxel-induced apoptosis in ovarian cancer cells, but
combining treatment with COX-2 inhibitors resulted in a sig-
niﬁcant inhibition of paclitaxel-induced apoptosis, suggesting
that combination of COX-2 inhibitors with chemotheraphy
agents does not have an additive or synergistic tumoricidal ef-
fect [52]. If the same eﬀect is true in vivo, the use of COX inhib-
itors prior to or concurrent with anticancer drug might carry a
negative eﬀect on therapeutic eﬃcacy. Although COX-2 selec-
tive inhibitors are obviously have chemopreventive potential, it
is necessary to examine carefully any adverse eﬀects at the
whole body level before considering their application for
clinical.
In summary, COX-2 upregulation contributes to induction
of apoptosis in MCF10A-ras cells treated with the anti-cancer
drug ET-18-O-CH3. These ﬁndings suggest that inhibition of
COX-2 expression is not necessarily desirable for cancer pre-
vention or therapy. It seems likely that the physiological func-
tions of COX-2 depend on the types of inducers and cells, and
targeted inhibition of COX-2 in the context of anticancer ther-
apy may need more through validation.
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